Prevent Blindness offers free resources on Thyroid Eye Disease, including a patient-focused episode, fact sheets, graphics, ...

On Friday, Viridian Therapeutics Inc (VRDN) stock saw a decline, ending the day at $20.14 which represents a decrease of $-1.50 or -6.93% from the prior close of $21.64. The stock opened at $21.72 and ...

Not for distribution to U.S. news wire services or for dissemination in the United States VANCOUVER, British Columbia, Nov. 06, 2024 (GLOBE NEWSWIRE) -- Viridian Metals Inc. (TSXV:VRDN) (the "Company" ...

Leerink Partners analyst Thomas Smith reiterated a Buy rating on Viridian Therapeutics (VRDN – Research Report) on November 12 and set a ...

H.C. Wainwright analyst Douglas Tsao maintained a Buy rating on Viridian Therapeutics (VRDN – Research Report) today and set a price ...

Third Quarter 2024 Results Key Financial Results Net loss: US$76.7m (loss ...

DATA Communications Management Corp. ("DCM" or the "Company"), a leading Canadian provider of print and digital solutions that help simplify complex marketing communications and workflow, today ...

Needham has recently reiterated Viridian Therapeutics Inc (VRDN) stock to Buy rating, as announced on September 11, 2024, according to Finviz. Earlier, on June 11, 2024, Wolfe Research had initiated ...

Viridian Therapeutics (VRDN) delivered earnings and revenue surprises of -3.60% and 4.88%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the ...

November 12, 2024--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company focused on discovering and developing potential best-in-class medicines for serious and rare ...